Source link : https://newshealth.biz/health-news/tafasitamab-combo-approved-for-r-r-follicular-lymphoma/
The US Food and Drug Administration has approved tafasitamab (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory (r/r) follicular lymphoma (FL). Lenalidomide with rituximab (R2) is already a common, chemotherapy-free option for FL in the first, and especially second, lines. Adding tafasitamab, an anti-CD19 immunotherapy, improved progression-free survival (PFS) from […]
The post Tafasitamab Combo Approved for r/r Follicular Lymphoma first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-19 05:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8